Form 4: Gossamer Bio CEO Awarded Performance Stock Units

Gossamer Bio's President and CEO, Faheem Hasnain, was granted 437,500 performance stock units, vesting upon key milestones related to seralutinib or a change in control.

Summary

• Faheem Hasnain, President & CEO and Director of Gossamer Bio, Inc. (GOSS), acquired 437,500 shares of common stock.
• The transaction occurred on October 1, 2025, at a price of $0 per share, indicating a performance stock unit (PSU) award.
• Following this transaction, Mr. Hasnain directly beneficially owns 557,793 shares of common stock.
• Additionally, 5,408,073 shares are indirectly beneficially owned by a family trust.
• The PSUs will vest in full upon the earlier of (i) the approval of a new drug application (NDA) for seralutinib or (ii) a change in control, provided these events occur on or prior to the fourth anniversary of the grant date and Mr. Hasnain maintains continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event (performance stock unit award). While not a direct financial performance indicator, it positively aligns management's incentives with key corporate milestones (NDA approval, change in control), which is generally viewed favorably by investors.

Positives

• The grant of performance stock units aligns executive compensation directly with key corporate objectives, specifically the approval of a new drug application for seralutinib.
• Tying vesting to a change in control provides an incentive for management to consider strategic alternatives that could maximize shareholder value.
• The award reinforces management's commitment and long-term interest in the company's success.

Negatives

• The vesting of the performance stock units is contingent on future events (NDA approval or change in control), meaning the value is not immediately realized and depends on successful execution of strategic and clinical goals.

Risks

• The performance stock units may not vest if the new drug application for seralutinib is not approved or if a change in control does not occur within the specified timeframe (fourth anniversary of the grant date).
• The value of the award is subject to the future stock price of Gossamer Bio, Inc., which can fluctuate based on market conditions and company performance.
• Continued employment is required for vesting, introducing a personal risk for the reporting person.

Future Outlook

The future outlook is tied to the successful development and regulatory approval of seralutinib, as well as potential strategic corporate actions such as a change in control, which would trigger the vesting of the awarded performance stock units.

Industry Context

The granting of performance-based equity awards to executive leadership is a common practice in the biotechnology and pharmaceutical industries. This approach aims to incentivize executives to achieve critical clinical and regulatory milestones, such as New Drug Application (NDA) approvals, which are significant value drivers in the sector.

Comparison to Industry Standards

• Performance-based equity awards are a standard component of executive compensation packages across the biotech industry, similar to practices at companies like Moderna, BioNTech, or Regeneron, where achieving clinical trial endpoints or regulatory approvals are key performance indicators.
• The specific vesting conditions tied to NDA approval for a key drug candidate (seralutinib) are highly relevant for a clinical-stage biotech company, aligning executive incentives with the company's primary value creation pathway.
• Including a change in control as a vesting trigger is also common, providing an incentive for management to consider M&A opportunities that could benefit shareholders.

Related Party Transactions

• The performance stock unit award to the President & CEO is a form of related party transaction (executive compensation) but is a standard, disclosed practice.

Stakeholder Impact

• Shareholders: The award aligns the CEO's financial interests with shareholder value creation through key drug development milestones and potential strategic transactions.
• Employees: No direct impact on general employees is indicated, but successful drug development could benefit all employees.

Next Steps

• Continued development and regulatory efforts for seralutinib towards New Drug Application (NDA) approval.
• Potential strategic evaluations regarding a change in control of the company.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (a performance stock unit award) and does not contain information that would fundamentally alter the investment thesis for Gossamer Bio. While the award aligns management incentives with key milestones, it does not provide new data on clinical trials, financial performance, or market conditions that would warrant a change in investment recommendation. Investors should continue to monitor the progress of seralutinib and broader company performance.

Keywords

Gossamer Bio, GOSS, Faheem Hasnain, performance stock units, PSU, equity award, executive compensation, seralutinib, NDA approval, change in control, insider transaction, Form 4